Oncolytics Biotech Achieves Success Criteria For Efficacy In The Third-Line Colorectal Cancer Cohort Of The Phase 1/2 GOBLET Study
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech has achieved success criteria for efficacy in the third-line colorectal cancer cohort of the Phase 1/2 GOBLET study.
October 23, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's successful results from the Phase 1/2 GOBLET study could potentially boost the company's stock in the short term.
The successful results from the Phase 1/2 GOBLET study indicate that Oncolytics Biotech is making significant progress in its colorectal cancer research. This could potentially attract more investors, leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100